Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bilski's Broad Sweep: Federal Circuit Says Vaccination Schedule Analysis Is Patentable

This article was originally published in The Pink Sheet Daily

Executive Summary

In Classen v. Biogen Idec the court rules that patents on a method of determining the administration schedule of vaccines are patent-eligible; the case applies the Supreme Court's Bilski decision on process patents to the biotech field.
Advertisement

Related Content

Hatch-Waxman Safe Harbor Ruling Wrong In GSK Case, Solicitor General Says, But Should Not Be Reviewed
Hatch-Waxman “Safe Harbor” Could Face Two-Front Battle In Supreme Court
Hatch-Waxman “Safe Harbor” Ruling Threatens Compound Patents, Momenta Says
Manufacturing Patents In Peril After Court Extends Hatch-Waxman “Safe Harbor”
Hatch-Waxman Safe Harbor Could Get Supreme Court Review
Supreme Court To Consider Prometheus Patents On Method Of Calibrating Drug Dosage
Supreme Court Loosens Rule On What Processes Can Be Patented
Supreme Court Loosens Rule On What Processes Can Be Patented

Topics

Advertisement
UsernamePublicRestriction

Register

PS072717

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel